The Possibilities for Solid Tumor Modeling With 3D Printers Are Just Beginning – OncLive | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Feeds:: Posts; Comments

« Cardiac arrest research dominates Eagles conference – EMS1.com

Myocardial ischemia – pipeline review, H1 2015 illuminated by new report – WhaTech »

The Possibilities for Solid Tumor Modeling With 3D Printers Are Just Beginning – OncLive

April 21, 2015 by 2012pharmaceutical

The Possibilities for Solid Tumor Modeling With 3D Printers Are Just Beginning – OncLive

Reporter: Aviva Lev-Ari, PhD, RN

See our Book

Medical 3D BioPrinting – The Revolution in Medicine

Technologies for Patient-centered Medicine:

From R&D in Biologics to New Medical Devices

@M3DP, LPBI Group

Available on Kindle Store @ Amazon.com since 12/30/2017

https://www.amazon.com/dp/B078QVDV2W

Three-dimensional printers are on the cusp of revolutionizing the way every doctor practices medicine.

Source: www.onclive.com

See on Scoop.it – Cardiovascular and vascular imaging

Posted in 3D Printing for Medical Application, BioPrinting in Regenerative Medicine, MicroEngineering Cell-Tissue & Systems | Leave a Comment

Leave a Reply Cancel reply

Follow Blog via Email

Enter your email address to follow this blog and receive notifications of new posts by email.

Email Address

Join 1,254 other subscribers
Recent Posts
- Press Release for Five Bilingual BioMed e-Series January 29, 2023
- 2022 FDA Drug Approval List, 2022 Biological Approvals and Approved Cellular and Gene Therapy Products January 17, 2023
- Verily announced other organizational changes, 1/13/2023 January 16, 2023
- Mission 4: Use of Systems Biology for Design of inhibitor of Galectins as Cancer Therapeutic – Strategy and Software December 13, 2022
- Science Has A Systemic Problem, Not an Innovation Problem December 12, 2022
- Chemistry Nobelist Carolyn Bertozzi’s years at UC Berkeley October 24, 2022
- Technion #1 in Europe in Field of AI for 2nd Straight Year October 20, 2022
- Endoglin Protein Interactome Profiling Identifies TRIM21 and Galectin-3 as New Binding Partners October 11, 2022
- The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells October 11, 2022
- Cancer Policy Related News from Washington DC and New NCI Appointments October 4, 2022
Archives
Archives
Categories
Categories
Meta

%d bloggers like this: